| Migraine |
1 |
1 |
| Food and Drug Administration (FDA) |
0 |
0.54 |
| Adverse Effects |
0 |
0.36 |
| Drug Interaction |
0 |
0.7 |
| Upper Respiratory Tract Infection |
0 |
0.25 |
| Aura |
0 |
0.18 |
| Board Certification |
0 |
0.18 |
| Brachial |
0 |
0.18 |
| Clinical Research |
0 |
0.75 |
| Experimental Drug |
0 |
0.18 |
| Grant |
0 |
0.18 |
| Match |
0 |
0.18 |
| Nausea |
0 |
0.18 |
| Neuro-Ophthalmology |
0 |
0.18 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.18 |
| Pandemic |
0 |
0.18 |
| Preventive Medicine |
0 |
0.8 |
| Preventive Screening |
0 |
0.95 |
| Salary and Compensation |
0 |
0.18 |
| Utah |
0 |
0.18 |
| Washington |
0 |
0.18 |
| Headache |
0 |
0.85 |
| Otolaryngology |
0 |
0.11 |
| Patient Safety |
0 |
0.1 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.05 |
| Constipation |
0 |
0.05 |
| HIV Infection |
0 |
0.05 |
| Revenue and Practice Management |
0 |
0.9 |